文献速递药疹与重症皮肤不良反应

Stevens-Johnson综合征与中毒性表皮坏死松解症的全身免疫调节治疗:系统综述与Meta分析

Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该系统综述与Meta分析纳入96项研究共3248例SJS/TEN患者,比较全身免疫调节治疗与支持治疗的死亡率差异。糖皮质激素在3项分析中均与生存获益相关,但仅1项有统计学意义;环孢素在唯一可行的个体患者数据分析中显示显著获益。静脉注射免疫球蛋白等其他治疗未见获益。

要点

  • 糖皮质激素在汇总数据中OR为0.5(95%CI 0.3-1.01),与生存获益相关但仅一项分析有统计学意义。
  • 环孢素在个体患者数据非分层模型中OR为0.1(95%CI 0.0-0.4),显示 promising 显著结果但样本量小。
  • 静脉注射免疫球蛋白等其他免疫调节治疗未观察到获益。

核心结论

  • 糖皮质激素和环孢素是SJS/TEN最有前景的全身免疫调节治疗,但需进一步前瞻性研究评估。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Web of Science、EMBASE、Scopus和Cochrane Library等数据库1990年1月至2012年12月文献并于2015年12月更新。
  • 初筛157项随机与非随机研究,最终纳入96项研究共3248例患者进行数据合成。
  • 采用随机效应模型汇总研究数据,并对个体患者数据进行logistic回归调整混杂因素,拟合分层与非分层两种模型。

主要发现

  • 糖皮质激素在汇总数据中OR为0.5(95%CI 0.3-1.01),个体患者数据非分层模型OR为0.7(95%CI 0.5-0.97),分层模型OR为0.8(95%CI 0.4-1.3)。
  • 环孢素在个体患者数据非分层模型分析中OR为0.1(95%CI 0.0-0.4),样本量小但结果显著。
  • 静脉注射免疫球蛋白等其他治疗未观察到获益。
  • 纳入的全身免疫调节治疗包括糖皮质激素、静脉注射免疫球蛋白、环孢素、血浆置换、沙利度胺、环磷酰胺、血液灌流、TNF抑制剂和粒细胞集落刺激因子。

关键数值与推荐

  • 糖皮质激素汇总数据OR 0.5(95%CI 0.3-1.01),个体患者数据非分层OR 0.7(95%CI 0.5-0.97),分层OR 0.8(95%CI 0.4-1.3)。
  • 环孢素个体患者数据非分层模型OR 0.1(95%CI 0.0-0.4)。
  • 静脉注射免疫球蛋白等其他治疗未见有益发现。

临床怎么用

  • 临床医生可参考本综述了解SJS/TEN各种全身免疫调节治疗的证据概况。
  • 糖皮质激素和环孢素可视为最有前景的治疗选择,但应结合患者具体情况并认识到证据局限性。
  • 静脉注射免疫球蛋白等其他治疗缺乏获益证据,不应常规推荐。

局限性

  • 所有分析包括非分层模型均存在局限性。
  • 环孢素相关分析患者样本量小。
  • 需要进一步前瞻性研究验证结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse reactions with high mortality. There is no evidence-based treatment, but various systemic immunomodulating therapies are used. OBJECTIVES: To provide an overview on possible immunomodulating treatments for SJS/TEN and estimate their effects on mortality compared with supportive care. DATA SOURCES: A literature search was performed in December 2012 for articles published in MEDLINE, MEDLINE Daily, MEDLINE Inprocess, Web of Science, EMBASE, Scopus, and the Cochrane Library (Central) from January 1990 through December 2012, and updated in December 2015, in the English, French, Spanish, and German languages looking for treatment proposals for SJS/TEN. Other sources were screened manually. STUDY SELECTION: Initially, 157 randomized and nonrandomized studies on therapies (systemic immunomodulating therapies or supportive care) for SJS/TEN were selected. DATA EXTRACTION AND SYNTHESIS: Relevant data were extracted from articles. Authors were contacted for further information. Finally, 96 studies with sufficient information regarding eligibility and adequate quality scores were considered in the data synthesis. All steps were performed independently by 2 investigators. Meta-analyses on aggregated study data (random-effects model) and individual patient data (IPD) (logistic regression adjusted for confounders) were performed to assess therapeutic efficacy. In the analysis of IPD, 2 regression models, stratified and unstratified by study, were fitted. MAIN OUTCOMES AND MEASURES: Therapy effects on mortality were expressed in terms of odds ratios (ORs) with 95% CIs. RESULTS: Overall, 96 studies (3248 patients) were included. Applied therapies were supportive care or systemic immunomodulating therapies, including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomide, cyclophosphamide, hemoperfusion, tumor necrosis factor inhibitors, and granulocyte colony-stimulating factors. Glucocorticosteroids were associated with a survival benefit for patients in all 3 analyses but were statistically significant in only one (aggregated data: OR, 0.5; 95%% CI, 0.3-1.01; IPD, unstratified: OR, 0.7; 95% CI, 0.5-0.97; IPD, stratified: OR, 0.8; 95% CI, 0.4-1.3). Despite the low patient size, cyclosporine was associated with a promising significant result in the only feasible analysis of IPD (unstratified model) (OR, 0.1; 95% CI, 0.0-0.4). No beneficial findings were observed for other therapies, including intravenous immunoglobulins. CONCLUSIONS AND RELEVANCE: Although all analyses, including the unstratified model, had limitations, glucocorticosteroids and cyclosporine were the most promising systemic immunomodulating therapies for SJS/TEN. Further evaluation in prospective studies is required. However, this work provides a comprehensive overview on proposed systemic immunomodulating treatments for SJS/TEN, which is of great relevance for treating physicians.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Zimmermann S, Sekula P, Venhoff M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017. PMID: 28329382. doi:10.1001/jamadermatol.2016.5668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。